EWA 401

Drug Profile

EWA 401

Alternative Names: EW-A-401; VEGF ZFP +434; VZ+434-P65; ZFP-Therapeutics; Zinc finger DNA binding protein - Sangamo

Latest Information Update: 11 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo BioSciences
  • Class Gene therapies; Vascular disorder therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Intermittent claudication; Ischaemic heart disorders; Peripheral vascular disorders

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 04 Jun 2008 Phase I development is ongoing
  • 21 May 2008 Pharmacodynamics data from a phase I trial in critical limb ischaemia released by Sangamo BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top